Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
October 19, 2017
Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines
SAN DIEGO, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it has entered into a research ...
October 19, 2017
Aimmune Therapeutics to Present Data on Peanut Allergy at ACAAI and PAAM Medical Meetings
BRISBANE, Calif.--(BUSINESS WIRE)-- Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on peanut ...
October 19, 2017
Arena Pharmaceuticals Announces Late Breaking Presentation of Positive Phase 2 Results with Ralinepag in Patients with Pulmonary Arterial Hypertension at the American College of Chest Physicians 2017 Annual Meeting
SAN DIEGO, Oct. 19, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that results of the Phase 2 clinical study of ralinepag (APD811), the Company's ...
October 19, 2017
CytoSorb® Usage During Valve Replacement Surgery for Infective Endocarditis Helps Stabilize Patients and May Improve Survival
MONMOUTH JUNCTION, N.J., Oct. 19, 2017 /PRNewswire/ -- CytoSorbents Corporation(CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically-ill and ...
October 18, 2017
Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
SAN DIEGO -- (BUSINESS WIRE) -- Ignyta, Inc. (RXDX), a biotechnology company focused on precision medicine in oncology, today announced updated results from its clinical trials, including the ...
October 18, 2017
BioLife Solutions to Present at Upcoming Investor Conferences
BOTHELL, Wash., Oct. 18, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic ...
October 18, 2017
FDA Advisory Committee Scheduled to Review TLANDO™ on January 10, 2018
SALT LAKE CITY, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration (“FDA”) ...
October 17, 2017
Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B
STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News: Transgene (TNG.PA) (Euronext Paris: TNG), a biotech company that designs and develops viral-based immunotherapies, will be presenting a poster on TG1050 first ...
October 17, 2017
STRATA Skin Sciences Announces Agreement with MedResults Network, a GPO Exclusive to the Aesthetic Medical Market
HORSHAM, Pa., Oct. 17, 2017 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to ...
October 17, 2017
Onxeo Reports First Instance Decision from the Commercial Court of Paris in the Lawsuit against SpeBio/SpePharm
PARIS, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO) (FR0010095596), (“Onxeo” or the “Company”), a biotechnology company specializing in the development ...
October 17, 2017
Pernix Therapeutics Announces Planned Departure of Chief Financial Officer
MORRISTOWN, N.J., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced that Graham ...
October 17, 2017
Sierra Oncology to Report Chk1 Inhibitor SRA737 Preclinical Data at AACR-NCI-EORTC 2017
VANCOUVER, Oct. 16, 2017 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) ...
October 17, 2017
Ignyta Receives European Medicines Agency Prime Designation for Entrectinib in NTRK Fusion-Positive Solid Tumors
SAN DIEGO--(BUSINESS WIRE) -- Ignyta, Inc. (RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the European Medicines Agency (EMA) has granted Priority Medicines ...
October 17, 2017
BrainStorm Announces Third Quarter 2017 Financial Results
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Oct. 17, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapies for ...
October 17, 2017
VBI Vaccines Hepatitis B Data Selected as Presidential Poster of Distinction at The Liver Meeting(R) 2017
CAMBRIDGE, MASSACHUSETTS -- (Marketwired - Oct 17, 2017) -- VBI Vaccines Inc. (VBIV)(VBV.TO) (VBI) today announced the company's abstract, "Antibody and Cell-mediated Immunity against PreS1, ...
October 13, 2017
Transgene: Peer Reviewed Scientific Publications Highlight TG4010’s Ability to Induce Broad CD8+ Responses and its Synergistic Effects in Combination with Immune Checkpoint Inhibitors
STRASBOURG, France -- (BUSINESS WIRE) -- Regulatory News: Transgene (TNG.PA), a biotech company that designs and develops viral-based immunotherapies, recently published two papers supporting the efficacy and ...
October 13, 2017
Mirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients
SAN DIEGO, Oct. 12, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical stage oncology biotechnology company, announced today that the Company has been included in ...
October 13, 2017
Prometic Announces FDA Acceptance of its Biologics License Application for Plasminogen (Ryplazim™)
LAVAL, QC, Oct. 13, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic) today announced that the U.S Food and Drug Administration (FDA) has accepted ...
October 13, 2017
Rexahn Announces $8 Million Registered Direct Offering
ROCKVILLE, Md., Oct. 13, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN) today announced it has entered into definitive agreements with institutional investors to ...
October 13, 2017
BioTime, Inc. Announces Pricing of $25.0 Million Public Offering of Common Stock
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (“BioTime”) (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative ...
Page 97 of 128